Type I Endometrial Adenocarcinoma

subtype

Identifier: CI-CAN-00008572
Entity page: /cancer/type-i-endometrial-adenocarcinoma ↗
Edges: 278

Neighbours: 15 genes15 drugs10 trials
Drawn: 40 of 40 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Type I Endometrial Adenocarcinoma altered in cohorts of …ALTERED_INderived15 of 200show all (up to 200)
← altered in cohorts of	PTEN 194 / 247 cases (79 %) · ssm · uec_cptac_gdc	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	ARID1A 136 / 247 cases (55 %) · ssm · uec_cptac_gdc

Type I Endometrial Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 31show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Type I Endometrial Adenocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Type I Endometrial Adenocarcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Type I Endometrial Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Type I Endometrial Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Everolimussmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Type I Endometrial Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Letrozolesmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Type I Endometrial Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Megestrolsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Type I Endometrial Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Type I Endometrial Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Abemaciclibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Type I Endometrial Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Anastrozolesmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Type I Endometrial Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Type I Endometrial Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Type I Endometrial Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Copanlisibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Type I Endometrial Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Dasatinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Type I Endometrial Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Dordavipronesmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Type I Endometrial Adenocarcinoma	1	Observed	clinicaltrials	graph →

Type I Endometrial Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 31show all (up to 200)

→ investigated in trials for

Paclitaxelsmall molecule

5 trials (2 active) · roll-up of the cancer and its descendants

—

Type I Endometrial Adenocarcinoma

Observed

Type I Endometrial Adenocarcinoma studied in …STUDIED_INderived10 of 47show all (up to 200)
→ studied in	NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped ONTOLOGY_EXACT · 47 trials mapped (25 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 47 trials mapped (25 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07078838Phase 2 · not yet recruiting Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer · condition mapped ALIAS · 47 trials mapped (25 active)	—	—	FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04604613active not recruiting Prediction of Recurrence Among Low Risk Endometrial Cancer Patients · condition mapped ONTOLOGY_EXACT · 47 trials mapped (25 active)	—	—	FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02397083Phase 2 · active not recruiting Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 47 trials mapped (25 active)	—	—	FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07812636early Phase 1 · not yet recruiting Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer · condition mapped ALIAS · 47 trials mapped (25 active)	—	—	FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05950464Phase 1 · recruiting Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer · condition mapped CURATED_BROADER · 47 trials mapped (25 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07349641Phase 2 · not yet recruiting A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 47 trials mapped (25 active)	—	—	FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03914612Phase 3 · active not recruiting Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 47 trials mapped (25 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05538897Phase 1/Phase 2 · active not recruiting Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers · condition mapped ONTOLOGY_EXACT · 47 trials mapped (25 active)	—	—	FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains